Pulmatrix (NASDAQ:PULM) Stock Crosses Above Fifty Day Moving Average – Here’s Why

Pulmatrix, Inc. (NASDAQ:PULM)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.48 and traded as high as $2.49. Pulmatrix shares last traded at $2.49, with a volume of 83,004 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Pulmatrix Stock Up 15.8%

The stock has a fifty day moving average of $2.48 and a 200-day moving average of $3.66.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC bought a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).